Read More

ALX Oncology Reported Phase 1 ASPEN-07 Data In in Patients with Advanced Bladder Cancer AT ASCO 2024; Initial Activity Showed Tumor Reduction In The Majority Of Evaluable Patients

ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented dataALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ:

ALXO